ALPANA Ventures

Resistell completes clinical pilot "performance evaluation study"

Our portfolio company Resistell just announced great results from its clinical pilot performance evaluation study.

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUVwith bacteremia or sepsis due to Gram-negative bacteria.

In the pilot study, the performance of Resistell AST was assessed for the most common bacteria/antibiotic combination, i.e. the most frequent cause of bacterial bloodstream infections at CHUVEscherichia coli and the beta-lactam antibiotic ceftriaxone. Thirty patients from CHUV volunteered to participate in the study. Resistell AST proved 100% accurate with both comparators. It provided results within 4 hours compared to 11 and 17 hours by Vitek2 and Kirby-Bauer, respectively.

Resistell_Press_Release_PES_completed_December_2021 (1)